Zobrazeno 1 - 10
of 56
pro vyhledávání: ''
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Kim Wai Yu, Laura Kruper, Yuan Yuan, Joanne E. Mortimer, Daphne Stewart, Louise Wong, Jae Jung, Samuel Chung, Sanjeet Dadwal, Jill Cooper
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose We update a patient series that reported a high incidence of infection with Gram-positive cocci in women treated with the combination of pertuzumab and trastuzumab and further characterize this clinical problem. Patients Treating physicians a
Autor:
Esin, Ece, Çakmak Öksüzoğlu, Berna, Bilici, Ahmer Erkan, Çiçin, İrfan, Köstek, Osman, Kaplan, Mehmet Ali, Aksoy, Sercan, Aktaş, Burak Yasin, Özdemir, Özlem, Alacaoğlu, Ahmet, Çabuk, Devrim, Sümbül, Ahmet Taner, Sakin, Abdullah, Paydaş, Şeyma, Yetişir, Evren, Er, Özlem, Korkmaz, Taner, Yıldırım, Nilgün, Şakalar, Teoman, Demir, Hacer, Artaç, Mehmet, Karaağaç, Mustafa, Harputluoğlu, Hakan, Bilen, E., Erdur, Erdur, Değirmencioğlu, Serkan, Aliyev, Altay, Cil, Timuçin, Olgun, P., Atalay Başaran, Gül, Gümüşay, Özge, Demir, Atakan, Tanrıkulu, Eda, Yumuk, Perran Fulden, İmamoğlu, İnanç, Oyan, Başak, Çetin, Bülent Eren, Haksöyler, Veysel, Karadurmuş, Nuri, Ertürk, İsmail, Evrensel, Türkkan, Yılmaz, Hasan, Beypınar, İsmail, Koçer, Murat, Pilancı, Kezbannur, Şeker, Mesut Metin, Ürün, Yüksel, Yıldırım, Nuriye O., Eren, Tülay, Demirci, Umut, Beypınar, İ.
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:131-143
PubMedID: 30377778 Purpose: In this study, we aimed to describe the real-life practice outcomes of pertuzumab–trastuzumab–taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients. Methods: This study wa
Autor:
Seiji Yoshitomi, Takayuki Iwamoto, Junji Matsuoka, Takayuki Motoki, Toshiharu Mitsuhashi, Tomohiro Nogami, Taeko Mizoo, Hisashi Tsuji, Tadahiko Shien, Yutaka Ogasawara, Hiroyoshi Doihara, Naruto Taira
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:289-294
Gemcitabine (Gem) with paclitaxel (Pac) is used for patients with metastatic breast cancer who require cytoreduction with manageable toxicities. Nanoparticle albumin-bound (nab)-Pac exhibits better efficacy and reduces the risk of hypersensitivity re
Autor:
Kevin P. Bethke, Oukseub Lee, Kara Kenney, Subhashini Allu, Irene Helenowski, Denise M. Scholtens, David Ivancic, Ali Shidfar, Nora M. Hansen, Robert T. Chatterton, Miguel Muzzio, Seema A. Khan, Megan E. Sullivan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:1235-1246
Women at high risk of breast cancer and those with carcinoma in situ need non-toxic, well-tolerated preventive interventions. One promising approach is drug delivery through the breast skin (local transdermal therapy, LTT). Our goal was to test novel
Autor:
Marc Buyse, Laura M Adamson, Norman Wolmark, Jame Abraham, Rachel C. Jankowitz, Antoinette R. Tan, Marni B. Tierno, Samuel A. Jacobs, Steven Limentani
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:1205-1212
Neratinib is an oral, small-molecule inhibitor that irreversibly binds to pan-HER (ErbB) receptor tyrosine kinases. Studies suggest that dual anti-HER therapies utilized in breast cancer patients are more efficacious than single agents in both the me
Autor:
Pliarchopoulou, K., Kalogeras, K. T., Kronenwett, R., Wirtz, R. M., Eleftheraki, A. G., Batistatou, Anna, Bobos, M., Soupos, N., Polychronidou, G., Gogas, H., Samantas, E., Christodoulou, C., Makatsoris, T., Pavlidis, Nicholas, Pectasides, Dimitrios, Fountzilas, George
Publikováno v:
Cancer chemotherapy and pharmacology
Purpose: RACGAP1 is a Rac GTPase-activating protein involved in cell growth regulation, cell transformation and metastasis. The aim of the present study was to explore the prognostic and/or predictive significance of RACGAP1 mRNA expression on diseas
Autor:
Ahmad Awada, Christophe Le Tourneau, Bojana Milojkovic Kerklaan, Anne-Sophie Govaerts, Hilde Rosing, Véronique Diéras, Alwin D. R. Huitema, Jos H. Beijnen, Marja Mergui-Roelvink, Martine Piccart-Gebhart, Jan H.M. Schellens, Sandrine Marreaud
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:53-62
This phase I study was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety profile, recommended dose for phase II studies, the pharmacokinetics, and antitumor activity of the combination of lonafarnib (farn
Publikováno v:
Cancer Chemotherapy and Pharmacology. 70:503-511
To determine the recommended dose (RD) of vinflunine in combination with trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and to investigate potential pharmacokinetic (PK) interactions.In the firs
Autor:
Joo Hee Yi, Ian E. Krop, Howard A. Burris, Bei Wang, Dan Lu, Manish Gupta, S. N. Holden, Sandhya Girish, Barbara Tong, Yu Waye Chu, Patricia LoRusso, Amita Joshi, Charles L. Vogel, Ola Saad
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker. To characterize the pharmacokinetics (PK) of T-DM1 in patien